Alzheimer's Disease Theranostics
-27 %

Alzheimer's Disease Theranostics

 Taschenbuch
Sofort lieferbar| Lieferzeit:3-5 Tage I

Unser bisheriger Preis:ORGPRICE: 103,95 €

Jetzt 75,78 €*

Alle Preise inkl. MwSt. | ggf. zzgl. Versand
ISBN-13:
9780128164129
Einband:
Taschenbuch
Erscheinungsdatum:
24.01.2019
Seiten:
80
Autor:
Magisetty (Scientist Obulesu
Gewicht:
188 g
Format:
193x235x6 mm
Sprache:
Englisch
Beschreibung:

1. Introduction: Alzheimer's Disease Pathology and Therapeutics 2. Early Diagnosis of Alzheimer's Disease: Pros and Cons 3. Antioxidants in Alzheimer's Therapy 4. Natural Compounds in the Treatment of Alzheimer's Disease 5. Blood Brain Barrier 6. Gene Therapy: The Cornerstone in the Development of Alzheimer's Disease Therapeutics 7. Viral vector therapeutics against Alzheimer's Disease 8. Mitochondria-Targeted Nanoparticles: A Milestone or a Mirage in the Treatment of Alzheimer's Disease 9. Nanoparticles: The Double-Edged Swords 10. Alzheimer Therapeutics: Pros and Cons
Alzheimer's Disease Theranostics discusses the latest information on recent theranostic avenues for both the diagnosis and treatment of Alzheimer's patients. It presents the pros and cons of the probable mechanistic role of nanoparticles in crossing the blood-brain barrier and improving disease symptoms. Finally, it highlights the merits of existing maneuvers and suggests perspectives to aid in future developments. Despite the difficulty of drug delivery to the brain, there are some nanoparticulate platforms demonstrating promise in treating neurodegenerative disorders such as Alzheimer's disease. Manifold theranostic maneuvers include antioxidants, natural bioactive compounds, gene therapy, and nanotechnological approaches, all of which are discussed in this important work.

Examines various theranostic applications for the diagnosis and treatment of Alzheimer's disease
Features a comprehensive overview of nanoparticle therapeutics in the area and use of antioxidants
Assesses the common challenges and lessons learned from blood-brain barrier challenges, viral vector approaches and mitochondria-targeted therapeutics